Palvella Therapeutics (PVLA) Non Operating Income (2014 - 2026)
Palvella Therapeutics (PVLA) reported Non Operating Income of -$32000.0 for Q1 2026, down 114.29% year-over-year from $224000.0 in Q1 2025, and up 96.07% quarter-over-quarter from -$815000.0 in Q4 2025.
Palvella Therapeutics (PVLA) Non Operating Income (2014 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has 13 years of Non Operating Income data on file, last reported at -$32000.0 in Q1 2026.
- Non Operating Income for Q1 2026 came in at -$32000.0, down 114.29% year-over-year; the trailing twelve-month figure through Mar 2026 was -$252000.0 (down 163.32% YoY), and the FY2025 annual result was $4000.0, changed N/A from the prior year.
- Non Operating Income grew to -$32000.0 in Q1 2026 per PVLA's latest filing, from -$815000.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $723000.0 in Q3 2022 and troughed at -$815000.0 in Q4 2025.
- A 5-year average of $165733.3 and a median of $130000.0 in 2024 frame the typical range for Non Operating Income.
- On a YoY basis, Non Operating Income climbed as much as 776.56% in 2025 and fell as far as 726.92% in 2025.
- A 5-year view of Non Operating Income shows it stood at $723000.0 in 2022, then tumbled by 41.36% to $424000.0 in 2023, then sank by 69.34% to $130000.0 in 2024, then sank by 726.92% to -$815000.0 in 2025, then jumped by 96.07% to -$32000.0 in 2026.
- Business Quant data shows PVLA's Non Operating Income at -$32000.0 in Q1 2026, -$815000.0 in Q4 2025, and $34000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 444,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 9.35 Mn |
| 10 | Palvella Therapeutics | 1.49 Bn | 1.23 Bn | - | -32,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32,000.00 |
| Dec 31, 2025 | -815,000.00 |
| Sep 30, 2025 | 34,000.00 |
| Jun 30, 2025 | 561,000.00 |
| Mar 31, 2025 | 224,000.00 |
| Dec 31, 2024 | 130,000.00 |
| Sep 30, 2024 | -20,000.00 |
| Jun 30, 2024 | 64,000.00 |
| Dec 31, 2023 | 424,000.00 |
| Sep 30, 2023 | 506,000.00 |
| Jun 30, 2023 | -161,000.00 |
| Mar 31, 2023 | -57,000.00 |
| Sep 30, 2022 | 723,000.00 |
| Jun 30, 2022 | 676,000.00 |
| Mar 31, 2022 | 229,000.00 |
| Dec 31, 2021 | 378,000.00 |
| Sep 30, 2021 | 678,000.00 |
| Jun 30, 2021 | 464,000.00 |
| Mar 31, 2021 | 884,000.00 |
| Dec 31, 2020 | -1.83 Mn |